{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:10:43Z","timestamp":1792084243653,"version":"4.4.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2017,12,12]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The measurement of disease-relevant biomarkers has become a major component of clinical trial design, but in the absence of rigorous clinical and analytical validation of detection methodology, interpretation of results may be misleading. In Huntington\u2019s disease (HD), measurement of the concentration of mutant huntingtin protein (mHTT) in cerebrospinal fluid (CSF) of patients may serve as both a disease progression biomarker and a pharmacodynamic readout for HTT-lowering therapeutic approaches. We recently published the quantification of mHTT levels in HD patient CSF by a novel ultrasensitive immunoassay-based technology and here analytically validate it for use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This work aims to analytically and clinically validate our ultrasensitive assay for mHTT measurement in human HD CSF, for application as a pharmacodynamic biomarker of CNS mHTT lowering in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The single molecule counting (SMC) assay is an ultrasensitive bead-based immunoassay where upon specific recognition, dye-labeled antibodies are excited by a confocal laser and emit fluorescent light as a readout. The detection of mHTT by this technology was clinically validated following established Food and Drug Administration and European Medicine Agency guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The SMC assay was demonstrated to be accurate, precise, specific, and reproducible. While no matrix influence was detected, a list of interfering substances was compiled as a guideline for proper collection and storage of patient CSF samples. In addition, a set of recommendations on result interpretation is provided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This SMC assay is a robust and ultrasensitive method for the relative quantification of mHTT in human CSF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jhd-170269","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T10:23:14Z","timestamp":1510309394000},"page":"349-361","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":63,"title":["Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay"],"prefix":"10.1177","volume":"6","author":[{"given":"Valentina","family":"Fodale","sequence":"first","affiliation":[{"name":"IRBM Science Park, Pomezia, Rome, Italy"},{"name":"IRBM Promidis, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Boggio","sequence":"additional","affiliation":[{"name":"IRBM Promidis, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Daldin","sequence":"additional","affiliation":[{"name":"IRBM Science Park, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cariulo","sequence":"additional","affiliation":[{"name":"IRBM Science Park, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carolina","family":"Spiezia","sequence":"additional","affiliation":[{"name":"IRBM Science Park, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Byrne","sequence":"additional","affiliation":[{"name":"University College London (UCL) Institute of Neurology","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"University of British Columbia","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"University College London (UCL) Institute of Neurology","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Macdonald","sequence":"additional","affiliation":[{"name":"CHDIManagement\/CHDI Foundation, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weiss","sequence":"additional","affiliation":[{"name":"IRBM Promidis, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bresciani","sequence":"additional","affiliation":[{"name":"IRBM Science Park, Pomezia, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2016.254649"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80743"},{"key":"e_1_3_2_4_2","first-page":"971","article-title":"The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","year":"1993","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell. 1993;72:971\u201383.","journal-title":"Cell"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040853"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26020"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26007"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep12166"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-9230(01)00599-8"},{"key":"e_1_3_2_11_2","unstructured":"Food and Drug Administration (2013) Guidance for Industry:Bioanalytical method validation. http:\/\/www.labcompliance.de\/documents\/FDA\/FDA-Others\/Laboratory\/f-507-bioanalytical-4252fnl.pdf"},{"key":"e_1_3_2_12_2","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on Bioanalytical Method Validation. European Medicines Agency London UK. (2011). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2009.08.001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096854"},{"key":"e_1_3_2_15_2","first-page":"1","article-title":"Scalable production in human cells and biochemicalcharacterization of full-length normal and mutant huntingtin","volume":"10","author":"Huang B","year":"2015","unstructured":"HuangB, LucasT, KueppersC, DongX, KrauseM, BepperlingA, et al. Scalable production in human cells and biochemicalcharacterization of full-length normal and mutant huntingtin. PLoS One. 2015;10:1\u201323. doi: 10.1371\/journal.pone.0121055","journal-title":"PLoS One"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.091181"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112262"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-9045-3"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000003390.51761.3d"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.130"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.093708"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00179"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3233\/RNN-2003-00229"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.4"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.075028"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5334.1990"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52014-2.00004-5"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/158797"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010980"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-170269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JHD-170269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-170269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:21Z","timestamp":1777453041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JHD-170269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12,12]]}},"alternative-id":["10.3233\/JHD-170269"],"URL":"https:\/\/doi.org\/10.3233\/jhd-170269","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}